Shoeshoe Mokhele

Dr. Shoeshoe Mokhele

Sefako Makgatho Health Sciences University, Pretoria, Gauteng, South Africa
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Gels
Verified
Journal Article
Open access
PDF file
LMLeshasha Trudy Mashabela
Leshasha Trudy Mashabela
MMMahlako Mokgaetji Maboa
Mahlako Mokgaetji Maboa
NMNtombi Florence Miya
Ntombi Florence Miya
TATaiwo O. Ajayi
Taiwo O. Ajayi
RCRumbidzai S. Chasara
Rumbidzai S. Chasara
MADAN POKAMADAN POKA
MADAN POKA
Gels are attractive candidates for drug delivery because they are easily producible while offering sustained and/or controlled drug release through various mechanisms by releasing the therapeutic agent at the site of action or absorption. Gels can be classified based on various characteristics including the nature of solvents used during preparation and the method of cross-linking. The development of novel gel systems for local or systemic drug delivery in a sustained, controlled, and targetable manner has been at the epitome of recent advances in drug delivery systems. Cross-linked gels can be modified by altering their polymer composition and content for pharmaceutical and biomedical applications. These modifications have resulted in the development of stimuli-responsive and functionalized dosage forms that offer many advantages for effective dosing of drugs for Central Nervous System (CNS) conditions. In this review, the literature concerning recent advances in cross-linked gels for drug delivery to the CNS are explored. Injectable and non-injectable formulations intended for the treatment of diseases of the CNS together with the impact of recent advances in cross-linked gels on studies involving CNS drug delivery are discussed.

24 May 2024 in Current Research in Pharmacology and Drug Discovery
Verified
Journal Article
Open access
KMKingsley Chimaeze Mbara
Kingsley Chimaeze Mbara
MFMarthe Carine D. Fotsing
Marthe Carine D. Fotsing
DNDerek Tantoh Ndinteh
Derek Tantoh Ndinteh
CMClaudine N. Mbeb
Claudine N. Mbeb
CNChinekwu Sherridan Nwagwu
Chinekwu Sherridan Nwagwu
CTClemence Tarirai
Clemence Tarirai
Diabetes mellitus (DM) is a global health burden that is characterized by the loss or dysfunction of pancreatic β-cells. In pancreatic β-cells, endoplasmic reticulum (ER) stress is a fact of life that contributes to β-cell loss or dysfunction. Despite recent advances in research, the existing treatment approaches such as lifestyle modification and use of conventional therapeutics could not prevent the loss or dysfunction of pancreatic β-cells to abrogate the disease progression. Therefore, targeting ER stress and the consequent unfolded protein response (UPR) in pancreatic β-cells may be a potential therapeutic strategy for diabetes treatment. Dietary phytochemicals have therapeutic applications in human health owing to their broad spectrum of biochemical and pharmacological activities. Flavonoids, which are commonly obtained from fruits and vegetables worldwide, have shown promising prospects in alleviating ER stress. Dietary flavonoids including quercetin, kaempferol, myricetin, isorhamnetin, fisetin, icariin, apigenin, apigetrin, vitexin, baicalein, baicalin, nobiletin hesperidin, naringenin, epigallocatechin 3-O-gallate hesperidin (EGCG), tectorigenin, liquiritigenin, and acacetin have shown inhibitory effects on ER stress in pancreatic β-cells. Dietary flavonoids modulate ER stress signaling components, chaperone proteins, transcription factors, oxidative stress, autophagy, apoptosis, and inflammatory responses to exert their pharmacological effects on pancreatic β-cells ER stress. This review focuses on the role of dietary flavonoids as potential therapeutic adjuvants in preserving pancreatic β-cells from ER stress. Highlights of the underlying mechanisms of action are also presented as well as possible strategies for clinical translation in the management of DM.

1 January 2020 in South African Journal of Botany
Verified
Journal Article
Open access
SMShoeshoe Mokhele
Shoeshoe Mokhele
DTD. Tswaledi
D. Tswaledi
OAO. Aboyade
O. Aboyade
JSJ. Shai
J. Shai
DKDavid Katerere
David Katerere

11 December 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RTRuvimbo Faith Tapera
Ruvimbo Faith Tapera
XNXavier Siwe Noundou
Xavier Siwe Noundou
LSLeshweni Jeremiah Jeremia Shai
Leshweni Jeremiah Jeremia Shai
SMShoeshoe Mokhele
Shoeshoe Mokhele
Helianthus tuberosus L. (Jerusalem artichoke) tubers and aerial parts possess both nutritional and therapeutic properties. The Jerusalem artichoke has been utilized for various applications, including its use as a functional food source, a reservoir of bioactive compounds, and a raw material to produce biofuels. Moreover, the Jerusalem artichoke is a rich source of an indigestible polysaccharide called inulin, which serves as a prebiotic that improves gastrointestinal health. This plant has been used globally throughout history as a dietary supplement, for pain treatment, to reduce swelling, and to boost the immune system, as well as to treat skin wounds in folk medicine. It is an abundant source of bioactive compounds, such as phenolic acids, coumarins, and flavonoids, which are known to exert pharmacological activities, including antioxidant, antimicrobial, and anti-inflammatory properties. The literature on its potential as an antidiabetic, anticancer, anti-fungistatic, antiviral, and anti-obesity agent, among others, is scanty. This review aims to provide a comprehensive overview of Helianthus tuberosus L.’s traditional uses, nutritional properties, secondary bioactive compounds, and pharmacological properties to further explore its health benefits.

29 June 2022 in Crystals
Verified
Journal Article
Open access
PDF file
Emmanuel Mukisa KiyongaEmmanuel Mukisa Kiyonga
Emmanuel Mukisa Kiyonga
LKLinda N. Kekani
Linda N. Kekani
Tinotenda Vanessa ChidziwaTinotenda Vanessa Chidziwa
Tinotenda Vanessa Chidziwa
KKKudzai Daisy Kahwenga
Kudzai Daisy Kahwenga
EBElmien Bronkhorst
Elmien Bronkhorst
Bwalya Angel WitikaBwalya Angel Witika
Bwalya Angel Witika
Cancer is a leading cause of death worldwide. It is a global quandary that requires the administration of many different active pharmaceutical ingredients (APIs) with different characteristics. As is the case with many APIs, cancer treatments exhibit poor aqueous solubility which can lead to low drug absorption, increased doses, and subsequently poor bioavailability and the occurrence of more adverse events. Several strategies have been envisaged to overcome this drawback, specifically for the treatment of neoplastic diseases. These include crystal engineering, in which new crystal structures are formed to improve drug physicochemical properties, and/or nanoengineering in which the reduction in particle size of the pristine crystal results in much improved physicochemical properties. Co-crystals, which are supramolecular complexes that comprise of an API and a co-crystal former (CCF) held together by non-covalent interactions in crystal lattice, have been developed to improve the performance of some anti-cancer drugs. Similarly, nanosizing through the formation of nanocrystals and, in some cases, the use of both crystal and nanoengineering to obtain nano co-crystals (NCC) have been used to increase the solubility as well as overall performance of many anticancer drugs. The formulation process of both micron and sub-micron crystalline formulations for the treatment of cancers makes use of relatively simple techniques and minimal amounts of excipients aside from stabilizers and co-formers. The flexibility of these crystalline formulations with regards to routes of administration and ability to target neoplastic tissue makes them ideal strategies for effectiveness of cancer treatments. In this review, we describe the use of crystalline formulations for the treatment of various neoplastic diseases. In addition, this review attempts to highlight the gaps in the current translation of these potential treatments into authorized medicines for use in clinical practice.

16 December 2025 in Next Materials
Verified
Journal Article
Open access
KMKingsley Chimaeze Mbara
Kingsley Chimaeze Mbara
YNYvonne Ngcobo
Yvonne Ngcobo
BCBetty Chivasa
Betty Chivasa
LMLethabo Masemola
Lethabo Masemola
RMRefilwe Mashamaite
Refilwe Mashamaite
CTClemence Tarirai
Clemence Tarirai